Sylentis is a biotech company founded in 2006 and wholly owned by Pharma Mar S.A. (PHM:SM), with the mission of building a solid and sustainable business and becoming a leader of a new class of medicines based on RNA interference or RNAi. RNAi is a promising approach to silence targets involved in many diseases and represents a new drug mechanism of action.
The Sylentis pipeline is aimed at indications with an elevated market potential, including ocular pathologies, inflammatory diseases and central nervous system diseases.
Given the inherent complications of this technology regarding delivery of the active principle to the target tissue, our strategy is based on first selecting accessible therapeutic targets, which don not require systemic administration of the product. However, the structural chemical modifications and the development of formulations for RNAi technology to increase the therapeutic effect of these molecules is an area of great interest to the company